Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/ PAF system activity in patients with chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 14, Issue 1, 2007, Pages 22-28

  Caini, P ^a   Guerra, C Tosti ^a   Giannini, C ^a   Giannelli, F ^a   Gragnani, L ^a   Petrarca, A ^a   Solazzo, V ^a   Monti, M ^a   Laffi, G ^a   Zignego, A L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hepatitis C virus; Platelet activating factor; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B100; MESSENGER RNA; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROTEIN MODIFICATION; RNA VIRUS; TISSUE SECTION; VIRUS PARTICLE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIVIRAL AGENTS; APOLIPOPROTEIN B-100; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VIREMIA;

EID: 33845736491     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00766.x     Document Type: Article

References (41)

1. Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003; 10(Suppl. 1): S27-S38.
2. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003; 7: 89-105.
3. Capra F, De Maria E, Lunardi C et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment. J Infect Dis 2000; 181: 425-431.
4. Kaplanski G, Maisonobe T, Marin V et al. Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia. J Hepatol 2005; 42: 334-340.
5. Cacoub P, Ghillani P, Revelen R et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 1999; 31: 598-603.
6. Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 2000; 1488: 102-123.
7. Prescott SM. Inflammatory actions of platelet-activating factor: control by PAF acetylhydrolase. J Investig Allergol Clin Immunol 1997; 7: 416.
8. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80: 1669-1699.
9. Tsoukatos DC, Liapikos TA, Tselepis AD, Chapman MJ, Ninio E. Platelet-activating factor acetylhydrolase and trans-acetylase activities in human plasma low-density lipoprotein. Biochem J 2001; 357: 457-464.
10. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (Berl) 1993; 182: 329-334.
11. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992; 181: 293-300.
12. Monazahian M, Bohme I, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-229.
13. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C irus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771.
14. Triyatni M, Saunier B, Maruvada P et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 2002; 76: 9335-9344.
15. Zignego AL, Macchia D, Monti M et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15: 382-386 (see comments).
16. Zignego AL, De Carli M, Monti M et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 1995; 47: 58-64.
17. Wu X, Zimmerman GA, Prescott SM, Stafforini DM. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem 2004; 279: 36158-36165.
18. Zignego AL, Ferri C, Giannelli F et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-580.
19. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93-114.
20. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999; 31: 369-376.
21. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 2002; 22: 727-733.
22. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30: S294-S301.
23. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 1990; 110: 529-540.
24. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155.
25. Quarck R, De Geest B, Stengel D et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500.
26. Hara M, Matsushima T, Satoh H et al. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol 2003; 23: 269-274.
27. Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1996; 3: 11-17.
28. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928.
29. Prescott SM. Platelet-activating factor: a phospholipid mediator of inflammation. In: Gallin J, Snyderman R, eds. Inflammation: basic principles and clinical correlates. Philadelphia: Lippincott, Williams, Wilkins, 1999: 387-396.
30. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995; 238: 5-20.
31. Stafforini DM. PAF acetylhydrolase gene polymorphisms and asthma severity. Pharmacogenomics 2001; 2: 163-175.
32. Cacoub P, Maisonobe T, Thibault V et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001; 28: 109-118.
33. Zignego AL, Ferri C, Giannini C et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996; 124: 31-34.
34. Ishizaka N, Ishizaka Y, Takahashi E et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 2002; 105: 1028-1030.
35. Ishizaka Y, Ishizaka N, Takahashi E et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67: 26-30.
36. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-566.
37. Tjoelker LW, Wilder C, Eberhardt C et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549-553.
38. Theilmeier G, De Geest B, Van Veldhoven PP et al. reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000; 14: 2032-2039.
39. Morgan EN, Boyle EM Jr, Yun W et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999; 100: II365-II368.
40. Noto H, Hara M, Karasawa K et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 829-835.
41. Hase M, Tanaka M, Yokota M, Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat 2002; 70: 107-118.